Table 1 The list of demographical and clinical information describing PD participants.

From: Automated video-based assessment of facial bradykinesia in de-novo Parkinson’s disease

Clinical characteristics

PD (n = 91; men n = 54)

General

 Age (years)

61.0 (12.3, 34–81)

 Symptom duration (years)

2.0 (1.7, 0.3–11.3)

Motor manifestations

 MDS-UPDRS III

29.8 (12.2, 6–63)

 Bradykinesia/Rigidity

19.9 ± (9.3, 3–46)

 PIGD

1.9 ± (1.7, 0–7)

Non-motor manifestations

 MoCA

25.0 ± (3.9, 17–30)

 BDI II

7.8 ± (4.7, 0–19)

Brain imaging (DAT-SPECT)

 Caudate binding ratio

3.0 ± (0.6, 1.3–4.3)

 Putamen binding ratio

1.5 ± (0.4, 0.9–2.3)

  1. Values are listed in in the format mean (standard deviation, range).
  2. PD Parkinson’s disease, MDS-UPDRS Movement Disorders Society – Unified Parkinson’s Disease Rating Scale, PIGD postural instability/gait difficulty, MoCA montreal cognitive assessment, BDI II Beck depression inventory II, DAT-SPECT dopamine transporter single-photon emission computed tomography.
Back to article page